
Pharmacally
Pancreatic Cancer
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Pancreatic Cancer
Clinical TrialsVerastem’s VS-7375 Shows 50% Response Rate in Pancreatic CancerVerastem Oncology reported a 50% confirmed objective response rate with investigational VS-7375 at 900 mg once daily in second-line KRAS G12D-mutant pancreatic cancer.Fact-Checked
Health TidingsLilly Secures FDA Breakthrough Therapy Designation for Olomorasib in KRAS G12C-Mutant Advanced Pancreatic CancerThe FDA has granted Breakthrough Therapy designation to Eli Lilly’s investigational KRAS G12C inhibitor olomorasib for adults with previously treated advanced pancreatic cancer harboring a KRAS G12C mutation.…Fact-Checked
Health TidingsNamodenoson Shows Durable Disease Control in Advanced Pancreatic CancerCan-Fite BioPharma will present Phase 2a data for Namodenoson at ESMO 2026 after the oral A3 adenosine receptor agonist demonstrated durable disease stabilization, encouraging survival, and a favorable…Fact-Checked
Health TidingsRevolution Medicines Advances Daraxonrasib Toward Europe After EMA Starts Phased Review for Pancreatic CancerThe EMA CHMP has initiated a phased review of Revolution Medicines’ oral RAS(ON) inhibitor daraxonrasib for pancreatic cancer, building on positive Phase 3 RASolute 302 results.Fact-Checked
Clinical TrialsRevolution Medicines Reports Promising Phase 1/2 Results for Zoldonrasib Combinations in KRAS G12D Pancreatic CancerRevolution Medicines unveiled promising Phase 1/2 results for zoldonrasib‑based regimens in metastatic KRAS G12D pancreatic cancer at the 2026 ESMO GI Congress.Fact-Checked
Clinical TrialsCan-Fite Reports Durable Survival with Namodenoson in Heavily Pretreated Pancreatic Cancer, Plans Phase 2b Combination TrialCan-Fite BioPharma has released updated Phase 2a results for Namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC).Fact-Checked
Clinical TrialsRevMed Advances Zoldonrasib into Phase 3 Pancreatic Cancer TrialRevolution Medicines has launched patient dosing in RASolute 305, a pivotal Phase 3 study testing the RAS(ON) G12D‑selective inhibitor zoldonrasib with frontline chemotherapy in metastatic pancreatic ductal adenocarcinoma.…Fact-Checked
Health TidingsElicio Narrows Phase 3 Focus for ELI-002 After Pancreatic Cancer Trial Reveals Benefit in R0 PatientsElicio Therapeutics reported mixed Phase 2 results for ELI-002 7P in resected KRAS-mutated pancreatic cancer.Fact-Checked
Clinical TrialsBicycle Therapeutics Highlights Nuzefatide Progress in Pancreatic CancerNew AACR 2026 data highlight clinical activity and tolerability of nuzefatide pevedotin, supporting its continued development in pancreatic cancer and other EphA2-expressing cancers.Fact-Checked
Medical DevicesNovocure Reports Encouraging Phase 2 Data for TTFields in Pancreatic CancerNovocure reported positive Phase 2 PANOVA-4 results showing TTFields therapy with atezolizumab and gemcitabine/nab-paclitaxel significantly improved disease control rate compared with historical chemotherapy outcomes in metastatic pancreatic cancer.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.